An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

Official Title: “An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures”

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Intervention(s) in this Clinical Trial

• Drug: travoprost, latanoprost, or bimatoprost
• Drug: Additional ocular hypotensive medication

Primary Measures

• Compliance.

Inclusion Criteria:

• Currently using one or two topical ocular hypotensive medications

Exclusion Criteria:

• Hypersensitivity to any component of medication

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Robin, Alan L., M.D. Other

Overall Clinical Trial Officials and Contacts

Alan L. Robin, MD Principal Investigator Alan L. Robin, M.D.  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00329095

Study ID Number: GMED-01

ClinicalTrials.gov Identifier: NCT00329095

Health Authority: United States: Institutional Review Board